Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Codexis Rejiggers Its Deal With Shell
by Ann M. Thayer
July 23, 2012
| A version of this story appeared in
Volume 90, Issue 30
Codexis is renegotiating its collaboration with Shell to allow it to develop and sell cellulase enzymes in the biofuels area, except in Brazil. Currently, only Shell can commercialize the enzymes for biofuels, while Codexis can sell them for other applications. In addition, the partners have agreed that as of Aug. 31, Shell can choose to stop funding between 13 and 48 full-time equivalent employees (FTEs) with only one day’s notice, instead of 90 days currently. If that happens, Codexis anticipates taking cost-cutting steps. As of May 10, Shell supports 116 FTEs at Codexis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X